A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2004
12/09/2004	US20040248971 Treating prostate cancer; suppress the expression of prostate-specific antigen
12/09/2004	US20040248967 Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same
12/09/2004	US20040248965 Indolin-2-one derivatives as anticarcinogenic agents for treating angiogenesis, lymphangiogenesis, filariasis
12/09/2004	US20040248941 such as 4-[2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]-1,3-dioxolan-2-one, used as prodrugs to lansoprazole; proton pump inhibitors; antiulcer agents
12/09/2004	US20040248936 such as (R)-1-{4-[4-(4-Phenoxy-2-propyl-phenoxy)-butoxy]-benzenesulfonyl}-azetidine-2-carboxylic acid, used as peroxisome proliferator-activated receptor agonists; hypoglycemic agents
12/09/2004	US20040248931 Poly(ADP-ribose)polymerase inhibitors; cerebral infarction; such as 3-[2-(3-hydroxypyrrolidin-1-yl)ethyl]-5-methyl-2H-isoquinolin-1-one; synthesis
12/09/2004	US20040248928 Cardiovascular system protection; ischemic attack, reperfusion, cardiac surgery
12/09/2004	US20040248923 Novel 4-anilinoquinoline-3-carboxamides
12/09/2004	US20040248919 Insulin sensitizers which do not increase triglyceride levels or suppress thyroid hormone axis; such as 7-[3,5-di-tert-butyl-2-(2,2-difluoroethoxy)-phenyl]-4-fluoro-3-methyl-octa-2,4,6-trienoic acid; synthesis; retinoid X receptor (rxr)
12/09/2004	US20040248916 Pyrimidine derivatives as selective inhibitors of cox-2
12/09/2004	US20040248914 Method for the treatment of overactive bladder
12/09/2004	US20040248913 (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators
12/09/2004	US20040248907 reacting 4,6-dichloro-5-nitropyrimidine with acyclic carboxy amines, then cyclization of the intermediates to form cellular adhesion inhibitors
12/09/2004	US20040248906 Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia
12/09/2004	US20040248902 Central nervous system, gastrointestinal and psycological disorders; such as 3-(4-chlorobenzenesulfonyl)-2-methyl-7-piperazin-1-yl-1H-indole; synthesis
12/09/2004	US20040248898 Group V and/or X secretory phospholipase A2 inhibition; suppressing degeneration of serum lipoproteins
12/09/2004	US20040248897 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions
12/09/2004	US20040248895 Novel guanidino compounds
12/09/2004	US20040248893 Isoxazolopyridinones
12/09/2004	US20040248891 Imidazotriazinone-containing compositions for nasal administration
12/09/2004	US20040248889 Analgesics; synthesis
12/09/2004	US20040248885 Use of thiazole derivatives for preparing a medicine for protecting mitochondria
12/09/2004	US20040248883 Novel heteroaryl derivatives, their preparation and use
12/09/2004	US20040248878 Lactam compound
12/09/2004	US20040248873 Photoreactive compounds and compositions
12/09/2004	US20040248871 Prevent cell differentiation
12/09/2004	US20040248867 Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
12/09/2004	US20040248852 Chemical compounds
12/09/2004	US20040248849 3-Aryl-A-oxy substituted propanoic acids and a process for their preparation
12/09/2004	US20040248844 Method for the treatment or prevention of Flavivirus infections using nucleoside analogues
12/09/2004	US20040248829 Gene expression in embryonic pancreas cells, adipocytes; prevent metabolic disorders; antidiabetic agents; obesity; eating disorders; neurodegenerative disorders
12/09/2004	US20040248817 Therapy for cardiovascular disorders; hypotensive agents; congestive heart failure
12/09/2004	US20040248810 Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
12/09/2004	US20040248790 eating regulator, a sleep regulator,.an arousal regulator, a pain regulator, a stress response regulator, a spontaneous behavior regulator or an emotional behavior regulator
12/09/2004	US20040248789 peptides/fusion inhibitors;
12/09/2004	US20040248787 fusion protein comprising a PTD (protein transduction domain) and an MITF (microphthalmia-associated transcripution factor) variant as an active ingredient with a His tag
12/09/2004	US20040248785 mutant factor VIII has procoagulant activity; increased half-life; substituted amino acid(s) in the A2 domain
12/09/2004	US20040248783 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments
12/09/2004	US20040248781 Therapeutic method for reducing angiogenesis
12/09/2004	US20040248778 Stable galenic freeze-dried pharmaceutical preparation of recombined carbohydrate-binding polypeptides
12/09/2004	US20040248772 yeast-derived ingredient having beta 1,3/1.6 glucan structure (IMMUTOL) or Norwegian Beta Glucan (TM); natural killer cell activating capabilities and tumor angiogenesis inhibiting capability by oral administration
12/09/2004	US20040248769 hydrolytic; inhibits arginyl endopeptidase or serine protease activity; air cleaner; fabric treatment
12/09/2004	US20040248767 Modulating serum amyloid a interaction with tanis and agents useful for same
12/09/2004	US20040248765 Tumour targeting prodrugs activated by metallo matrixproteinases
12/09/2004	US20040248324 Fhm a novel member of the TNF ligand supergene family: materials and methods for interaction modulators
12/09/2004	US20040248252 Nucleotide sequences coding mammalian histamine H4 receptor protein for use in diagnosis, prevention and treatment of asthma, allergy, inflammation, thrombotic, cardiovascular and autoimmune disorders
12/09/2004	US20040248249 Protein for use in treatment, prevention and diagnosis of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders
12/09/2004	US20040248240 Nucleotide sequences coding membrane protein for use in identifying modulator for treatment of pain management, epilepsy, stroke, ischemia and heart disease
12/09/2004	US20040248214 Monitoring natural killer cell activity in humans; antitumor agents; immunotherapy
12/09/2004	US20040248209 Identifying modulators which modify binding activity of isoprenoids and membrane protein receptors for use in treatment of diabetes, obesity, pain, inflamatory, cardiovascular, cancer and liver disorders
12/09/2004	US20040248207 Sodium channel regulators and modulators
12/09/2004	US20040248196 Methods of screening based on the egf receptor crystal structure
12/09/2004	US20040248173 Nucleotide sequences coding cyclic peptide receptor for use in identifying modulators for treatment of pituitary hormone, epinephrine release, gastrointestinal, cardiovascular, electrolyte balance, hypertensive, diabetic and respiratory system disorder
12/09/2004	US20040248083 Viral plasmid comprising heterologous or synthetic dimerisation sequences which promotes dimer formation of plasmid transcripts and prevents recombination between plasmid transcripts and another retrovirus present in genome; gene transfer tool; bioreactor
12/09/2004	US20040247693 Modifying the fatty acid composition of cell membranes of organs and tissues
12/09/2004	US20040247681 An acrylated polypropylene glycol or 1,2-propylene oxide adduct copolymerized with an acrylic silyl ester or an acrylic ketone; controlled release ocular inserts; glaucoma, cataracts
12/09/2004	US20040247676 The active and barrier layers each contain two or more hydrophilic polymers, a lipophilic substance, and an adjuvant; side effect reduction; single daily dosage
12/09/2004	US20040247659 (Ester)-lysolecithins in liposomes
12/09/2004	US20040247658 Delivery system with increased bioavailability
12/09/2004	US20040247621 Combination therapy using a synergistic mixture of mechlorethamine, nitrogen mustard N-oxide, melphalan, uramustin, ifosfamide, chlorambucil, or cyclophosphamide and an anti-interleukin-6 receptor antibody; anticarcinogenic agents
12/09/2004	US20040247609 Administering a non-specific immunopotentiator before administering an antigen protein ; particularly administering a cancer antigen protein, WT1, or a peptide derived from the WT1 protein in combination with a bacterium-derived component or IFN-alpha
12/09/2004	US20040247604 Anti-inflamatory fatty alcohols and fatty acid esters useful as antigen carriers
12/09/2004	US20040247598 In particular of delayed-type hypersensitivity; especially administering an IL-18 binding protein or a derivative, an expression vector or a genetically engineered cell, optionally with an antiinflammatory agent such as a COX-inhibitor.
12/09/2004	US20040247597 Method of treating atherosclerosis and other inflammatory diseases
12/09/2004	US20040247595 Related to the potassium channel subfamily; can be used as models for the development of and aid in the identification of therapeutic proteins that modulate transporter activity
12/09/2004	US20040247564 Treating a tissue disorder involving a loss and/or apoptosis of cells by administering an agent that induces phosphorylation and/or activation of protein kinase B to cause proliferation; particularly administering a human stromal-derived factor-1 and a G-CSF to cause proliferation of cardiomyocytes
12/09/2004	US20040246627 Disc drive pivot bearing assembly
12/09/2004	CA2527429A1 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
12/09/2004	CA2527109A1 Oligo double-stranded rna inhibiting the expression of bcl-2 and medicinal composition containing the same
12/09/2004	CA2525695A1 Compositions and foods and drinks containing higher fatty acid derivative
12/09/2004	CA2524090A1 Use of tripolidine in providing refreshedness on waking
12/08/2004	EP1484402A2 Antibody for use in therapy
12/08/2004	EP1484400A1 Sodium-independent transporter carrying acidic amino acid and its gene
12/08/2004	EP1484339A2 Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
12/08/2004	EP1484333A1 New aminopropylphosphonous acids
12/08/2004	EP1484327A1 Nitrogenous heterocyclic compound and medicine thereof
12/08/2004	EP1484322A1 Process for producing optically active sulfoxide derivative
12/08/2004	EP1484320A1 Jnk inhibitor
12/08/2004	EP1484313A1 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
12/08/2004	EP1484061A1 Drugs containing riboflavin-type compounds
12/08/2004	EP1484059A2 Antiviral composition comprising phenylacetic acid derivatives
12/08/2004	EP1484058A2 Pharmaceutical composition for inhibiting altering gene expression and for inducing differentiation in non-malignant cells
12/08/2004	EP1484055A1 Delivery system with increased bioavailability
12/08/2004	EP1483978A1 Biological process for the production of a food product comprising heme-iron and food product obtained with said process
12/08/2004	EP1483575A2 Methods for isolating ligands e.g. t cell epitopes
12/08/2004	EP1483375A1 A method for producing recombinant viruses using site-specific recombination
12/08/2004	EP1483374A2 Use of l-alpha-lysophosphatidycholine to obtain the differentiation of monocytes in mature dendritric cells in vivo
12/08/2004	EP1483297A2 Antibodies derived from anti ed-b l19 and targeting tumor vasculature
12/08/2004	EP1483290A2 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments
12/08/2004	EP1483285A1 INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME
12/08/2004	EP1483284A2 Selective dipeptide inhibitors of kallikrein
12/08/2004	EP1483270A1 Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase
12/08/2004	EP1483268A2 Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
12/08/2004	EP1483267A2 Microtubule stabilizing compounds
12/08/2004	EP1483266A1 Spiro compounds with npy antagonistic activity
12/08/2004	EP1483265A1 Purine derivatives as kinase inhibitors
12/08/2004	EP1483264A2 1-allyl ergot alkaloid derivatives, method for producing the same and the use thereof for preventing and treating migraine
12/08/2004	EP1483263A1 Thiazolyl urea compounds for the treatment of cancer
12/08/2004	EP1483261A1 Phthalimide carboxylic acid derivatives
12/08/2004	EP1483260A1 Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament

1 ... 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 ... 1564